Nu-Med Plus (NUMD) notifies SEC of late 10-K, plans April 15, 2026 filing

Rhea-AI Filing Summary

Nu-Med Plus, Inc. notified the SEC it will file its Annual Report on Form 10-K for the period ended December 31, 2025 after the prescribed deadline under Rule 12b-25.

The company states it is completing audited financial statements and expects to file the 10-K on or before April 15, 2026. The company indicates no anticipated significant change in results of operations versus the prior year.

Insights

Compliance Officer

Routine late-filing notice citing audited financials; company sets an April 15, 2026 cure date.

Nu-Med Plus invoked Rule 12b-25 to notify the Commission that its Form 10-K for the period ended December 31, 2025 will be filed on or before April 15, 2026. The filing attributes the delay to completion of audited financial statements.

There is no assertion of a material change in operating results in the notice. Subsequent filings will confirm final figures; stakeholders should watch for the filed 10-K and any auditor statement or exhibit attached to that filing.

Key Figures

Period ended: December 31, 2025 Expected filing date: April 15, 2026 SEC file number: 000-54808 +2 more

5 metrics

Period ended December 31, 2025 Annual reporting period for the Form 10-K

Expected filing date April 15, 2026 Anticipated date to file the Form 10-K under Rule 12b-25

SEC file number 000-54808 Identifies the registrant's SEC file

CUSIP 67021R 10 4 Security identifier listed on the notification

Contact phone (631) 403-4337 Contact for the notification (William Hayde, CEO)

Key Terms

Rule 12b-25, Form 12b-25 (NT 10-K), audited financial statements

3 terms

Rule 12b-25 regulatory

"If the subject report could not be filed without unreasonable effort or expense"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 12b-25 (NT 10-K) regulatory

"FORM 12b-25 NOTIFICATION OF LATE FILING"

audited financial statements financial

"The Company is in the process of completing its audited financial statements"

Audited financial statements are a company's financial reports—like its income, expenses, assets and debts—that have been examined and verified by an independent accountant to confirm they are accurate and complete. For investors, an audit is like having a trusted mechanic inspect a used car: it increases confidence that the financial picture is reliable, reduces the risk of hidden problems, and supports better decisions about valuing or trusting the company.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

SEC FILE NUMBER 000-54808

CUSIP NUMBER 67021R 10 4

(Check One) [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR

For the Period Ended December 31, 2025

[ ] Transition Report on Form 10-K

[ ] Transition Report on Form 20-F

[ ] Transition Report on Form 11-K

[ ] Transition Report on Form 10-Q

[ ] Transition Report on Form N-SAR

For the Transition Period Ended ________________

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Full Name of Registrant:	Nu-Med Plus, Inc.
Former Name if Applicable:	N/A
Address of Principal Executive Office:	640 Belle Terre Rd, Building 2 E Port Jefferson, NY 11777

PART II - RULES 12b-25 (b) and (c)

If the subject report could not be filed without unreasonable effort or expense, and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) [X]

(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date.

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

The Company is in the process of completing its audited financial statements, and believes that the subject Annual Report will be available for filing on or before April 15, 2026.

PART IV - OTHER INFORMATION

(1) Name and address of person to contact in regard to this notification:

William Hayde

640 Belle Terre Rd, Building 2 E

Port Jefferson, NY 11777

Telephone: (631) 403-4337

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the Registrant was required to file such report(s) been filed?

If the answer is no, identify report(s). [X] Yes [ ] No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

[ ] Yes [X] No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

NU-MED PLUS, INC. has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 31, 2026

By/s/William Hayde

William Hayde, CEO, Principal Executive

FAQ

What did Nu-Med Plus (NUMD) file with the SEC?

Nu-Med Plus filed a Form 12b-25 notifying a late Form 10-K filing. The notice states the 10-K covers the period ended December 31, 2025 and cites completion of audited financial statements.

When does Nu-Med Plus expect to file its 10-K?

The company expects to file the Annual Report on Form 10-K on or before April 15, 2026. That date is provided as the anticipated cure under Rule 12b-25.

Does the late filing notice say results will change materially?

No. The notice states no anticipated significant change in results of operations compared to the prior fiscal year, per the responses on the form.

Who is the contact for this notification?

The contact listed is William Hayde, CEO, at 640 Belle Terre Rd, Building 2 E, Port Jefferson, NY 11777 with phone (631) 403-4337 for questions about the late filing.

What is Rule 12b-25 and how does it apply here?

Rule 12b-25 permits a registrant to notify the SEC of a late filing when additional time is needed. Nu-Med Plus used it to state the reason and expected cure date of April 15, 2026.